Your Messages Inbox
Your Article Summary
See Latest ArticlesEncouraging first data on new targeted treatment for patients with melanoma - the deadliest form of skin cancer
Roche, 06/02/09
Roche announced results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients with advanced melanoma whose cancer harbours the BRAF mutation. Patients treated with PLX4032 lived for a median of at least six months without their disease getting worse and experienced shrinkage of their tumours; this included patients where the cancer had spread to the liver, lung and bone. Historically, metastatic melanoma patients live less than two months before their disease progresses.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
GlaxoSmithKline, 12/15/09
New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-positive Breast Cancer
Genentech, 12/15/09
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline, 12/15/09
Article Search
Sponsor